Prognostic evaluation in multiple myeloma:: an analysis of the impact of new prognostic factors

被引:0
|
作者
Turesson, I [1 ]
Abildgaard, N
Ahlgren, T
Dahl, IM
Holmberg, E
Hjorth, M
Nielsen, JL
Odén, A
Seidel, C
Waage, A
Westin, J
Wislöff, F
机构
[1] Malmo Univ Hosp, Dept Med, S-20502 Malmo, Sweden
[2] Aarhus Univ Hosp, Dept Med & Haematol, DK-8000 Aarhus, Denmark
[3] Univ Tromso Hosp, Dept Med, N-9038 Tromso, Norway
[4] Sahlgrens Univ Hosp, Ctr Oncol, S-41345 Gothenburg, Sweden
[5] Lidkoping Hosp, Dept Med, Lidkoping, Sweden
[6] Norwegian Univ Sci & Technol, Inst Canc Res & Mol Biol, N-7034 Trondheim, Norway
[7] Univ Trondheim Hosp, Dept Med, N-7006 Trondheim, Norway
[8] Univ Lund Hosp, Dept Med, S-22185 Lund, Sweden
[9] Ullevaal Univ Hosp, Dept Med, Oslo, Norway
关键词
multiple myeloma; survival; prognostic factors; risk score;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We have analysed the prognostic information for survival of presenting features in an unselected series of 394 myeloma patients. 15 variables with significant prognostic information were identified, among these were some not previously or only recently reported: serum levels of hepatocyte growth factor (HGF), interleukin-6 (IL-6), C-terminal crosslinked telopeptide of collagen I (ICTP) and soluble interleulrin-6 receptor (siL-6R). In a multivariate Cox analysis six variables were significantly and independently associated with poor survival: high age, low W.H.O.-performance status (PS), high serum levels of calcium, beta-2-microglobulin (beta-2M), IL-6 and sIL-6R, A risk score formed to predict survival for each percentile of the patient population allowed an efficient separation of prognostic groups. The discriminating power of the model compared favourably with three other previously published staging systems applied to the study population, Exclusion of IL-6 and sIL-6R from the model only marginally decreased the efficacy of the separation. The predictive value of some variables (sIL-6R, beta-2M and W.H.O.-PS) decreased significantly over time. We conclude that formation of a risk score based on independent variables is an efficient way to separate prognostic groups, that the contribution of new and not easily available parameters should be thoroughly evaluated before inclusion in prognostic models for clinical use and that the predictive value of parameters may decrease over time.
引用
收藏
页码:1005 / 1012
页数:8
相关论文
共 50 条
  • [21] Prognostic Impact Of Comorbidity In Multiple Myeloma
    Rios Tamayo, Rafael
    Martinez Lopez, Joaquin
    Jurado, Manuel
    Clavero Sanchez, Maria Esther
    Lopez Jimenez, Fatima
    Paciello Coronel, Maria Liz
    Garcia Fernandez, Jose Ramon
    de la Torre, Youssef Moatassim
    Lopez Berenguel, Francisco
    Ferrer, Rosario Leyva
    Sainz Perez, Juan
    Molina Portillo, Elena
    Sanchez Perez, Maria Jose
    de Pablos Gallego, Jose Maria
    Lopez Garrido, Pilar
    Jimenez Moleon, Jose Juan
    Lopez de Lacalle, Amaia
    Lahuerta Palacios, Juan Jose
    BLOOD, 2013, 122 (21)
  • [22] Prognostic Impact of Hyperdiploidy on Multiple Myeloma in the Era of New Agents
    Wang, Yi
    Zhuang, Jing
    An, Gang
    Mao, Xue-Han
    Du, Chenxing
    Liu, Jiahui
    Fan, Huishou
    Deng, Shuhui
    Xu, Yan
    Sui, Weiwei
    Qiu, Lugui
    BLOOD, 2020, 136
  • [23] Conditional survival in multiple myeloma and impact of prognostic factors over time
    Nadine H. Abdallah
    Alexandra N. Smith
    Susan Geyer
    Moritz Binder
    Patricia T. Greipp
    Prashant Kapoor
    Angela Dispenzieri
    Morie A. Gertz
    Linda B. Baughn
    Martha Q. Lacy
    Suzanne R. Hayman
    Francis K. Buadi
    David Dingli
    Yi L. Hwa
    Yi Lin
    Taxiarchis Kourelis
    Rahma Warsame
    Robert A. Kyle
    S. Vincent Rajkumar
    Shaji K. Kumar
    Blood Cancer Journal, 13
  • [24] Conditional survival in multiple myeloma and impact of prognostic factors over time
    Abdallah, Nadine H.
    Smith, Alexandra N.
    Geyer, Susan
    Binder, Moritz
    Greipp, Patricia T.
    Kapoor, Prashant
    Dispenzieri, Angela
    Gertz, Morie A.
    Baughn, Linda B.
    Lacy, Martha Q.
    Hayman, Suzanne R.
    Buadi, Francis K.
    Dingli, David
    Hwa, Yi L.
    Lin, Yi
    Kourelis, Taxiarchis
    Warsame, Rahma
    Kyle, Robert A.
    Rajkumar, S. Vincent
    Kumar, Shaji K.
    BLOOD CANCER JOURNAL, 2023, 13 (01)
  • [25] New prognostic biomarkers in multiple myeloma
    Szudy-Szczyrek, Aneta
    Szczyrek, Michal
    Soroka-Wojtaszko, Maria
    Hus, Marek
    POSTEPY HIGIENY I MEDYCYNY DOSWIADCZALNEJ, 2016, 70 : 811 - 819
  • [26] PROGNOSTIC FACTORS FOR MULTIPLE-MYELOMA IN THE DOG
    MATUS, RE
    LEIFER, CE
    MACEWEN, EG
    HURVITZ, AI
    JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION, 1986, 188 (11): : 1288 - 1292
  • [27] PROGNOSTIC FACTORS AND MONITORING OF MULTIPLE-MYELOMA
    ESCHARD, JP
    PIGNON, B
    REVUE DE MEDECINE INTERNE, 1992, 13 (04): : 273 - 277
  • [28] Genetic markers as prognostic factors in multiple myeloma
    Conte L, Guillermo
    Braggio, Esteban
    Figueroa, Gaston
    Fonseca, Rafael
    REVISTA MEDICA DE CHILE, 2009, 137 (04) : 552 - 558
  • [29] PROGNOSTIC FACTORS AND CLASSIFICATION IN MULTIPLE-MYELOMA
    MIGUEL, JFS
    SANCHEZ, J
    GONZALEZ, M
    BRITISH JOURNAL OF CANCER, 1989, 59 (01) : 113 - 118
  • [30] Prognostic factors in multiple myeloma: It's in the genes
    Bergsagel, PL
    CLINICAL CANCER RESEARCH, 2003, 9 (02) : 533 - 534